gastric cancer
Conditions
Interventions
experimental group:Methanesulfonate Apatinib and paclitaxel.
Sponsors
Hubei Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age: >= 18 years old, male or female; 2. Patients with pathologically or histologically confirmed gastric cancer (CT3-T4A, N + , M0 and all patients with T4B and any metastatic advanced gastric cancer) , disease progression after first-line therapy (if the interval between the end of adjuvant or neoadjuvant therapy and the first progression is less than 6 months) 3. According to Recist1.1, there is at least one measurable lesion; 4. ECOG score 0-1; 5. Expected survival period of more than 3 months; 6. Volunteer for the study and sign an informed consent form; 7. Researchers think there could be benefits.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Exclude patients with contraindications to antiangiogenic drugs: 1) people with high blood pressure who can not be controlled with antihypertensive medication; 2) urine routine showed protein positive >= + + ; 3) having multiple factors (inability to swallow, chronic diarrhea, intestinal obstruction, etc.) that affect oral medication; 4) abnormal coagulation function and bleeding tendency, such as active ulcer, occult blood in stool (+ +) , etc. 5) grade 3-4 cardiac insufficiency (NYHA standard); 6) severe hepatic and renal dysfunction (grade 4); 3. A History of blackstool and/or hematemesis within 3 months; 4. Patients receiving thrombolytic or anticoagulant therapy. 5. According to the researchers judgment, there is a serious concomitant disease that endangers the patients safety or affects the patients ability to complete the study. 6. Expected survival time less than 3 months 7. The Doctor doesnt think its a good fit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;ORR;DCR;EORTC QLQ-C30 V3.0?HCC-18;AE; | — |
Countries
China
Contacts
Public ContactWei Shaozhong
Hubei Cancer Hospital
Outcome results
None listed